Article
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
The Lancet. Oncology - 1 Nov 2017
Wu Yi-Long, Cheng Ying, Zhou Xiangdong, Lee Ki Hyeong, Nakagawa Kazuhiko, Niho Seiji, Tsuji Fumito, Linke Rolf, Rosell Rafael, Corral Jesus, Migliorino Maria Rita, Pluzanski Adam, Sbar Eric I, Wang Tao, White Jane Liang, Nadanaciva Sashi, Sandin Rickard, Mok Tony S
Abstract excerpt
BACKGROUND: Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor. We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in the first-line treatment of patients with advanced EGFR-mutation-positive non-small-cell lung cancer (NSCLC). METHODS: In this international, multicentre, randomised, open-label, phase 3 study (ARCHER 1050), we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.